Transforming CKD Care: The Next Chapter in Treatment

Chronic kidney disease (CKD) is a growing global health concern, with Singapore facing a particularly significant burden. Currently, approximately 500,000 individuals in Singapore suffer from CKD, and projections suggest that by 2035, one in four people may be affected. Diabetes remains the leading cause of CKD in the country, accounting for 67% of kidney failure cases.

In addition to optimal blood pressure and glycaemic control, as well as lifestyle modifications, the treatment landscape for diabetic kidney disease has evolved to include renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter 2 inhibitors (SGLT2i), and non-steroidal mineralocorticoid receptor antagonist (MRA) as key therapeutic strategies. More recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as game-changers across the cardiovascular-kidney-metabolic spectrum.

This presentation will highlight the latest scientific evidence supporting the role of GLP-1 RAs in the treatment algorithm for kidney disease. Clinical data demonstrating their impact on kidney outcomes will be discussed alongside patient case studies, providing insights into their potential to reshape CKD management in diabetic patients.